<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943175</url>
  </required_header>
  <id_info>
    <org_study_id>H-1207-117-419</org_study_id>
    <secondary_id>A120476</secondary_id>
    <nct_id>NCT01943175</nct_id>
  </id_info>
  <brief_title>Stem Cell Research on Subjects at Genetic High Risk for Schizophrenia</brief_title>
  <official_title>Stem Cell-based Approaches to Neuronal Characteristics and Endophenotype of Schizophrenia in Genetic High Risk Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health &amp; Welfare, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at finding endophenotypes of schizophrenia at neuronal level by obtaining
      stem cells which is derived from adipose cells of subjects with heavy genetic loading for
      schizophrenia then differentiating them into neuronal cells.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Structural and functional characteristics of neurons differentiated from adipose tissue derived stem cells in subjects with genetic high risk for schizophrenia and healthy controls</measure>
    <time_frame>three years</time_frame>
    <description>in vitro measurement of the expression of the neuronal markers for differentiated post-mitotic neuron, GABAergic/Glutamatergic neuron.
The neuronal connectivity, neurites from soma and synaptic protein levels will be assessed. In addition, RNA and proteins expression (e.g. Glutamate/GABA receptors) , physiological function, and in vitro response to antipsychotics will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAARMS(Comprehensive assessment of at risk mental states)</measure>
    <time_frame>Baseline</time_frame>
    <description>Clinical rating scale for prodromal symptoms of psychosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS(Positive and Negative Syndrome Scale)</measure>
    <time_frame>Baseline</time_frame>
    <description>Clinical rating scale for the assessment of symptoms of schizophrenia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function test battery (composite)</measure>
    <time_frame>Baseline</time_frame>
    <description>Neurocognitive function battery comprising tests measuring subjects' intelligence, attention, memory, executive function and social cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ERP(event-related potential) profile</measure>
    <time_frame>Baseline</time_frame>
    <description>ERP profile including P50, P30 &amp; MMN(Mismatch Negativity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural/resting functional MRI data</measure>
    <time_frame>Baseline</time_frame>
    <description>Structural/resting functional MRI data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proton MR spectroscopy</measure>
    <time_frame>Baseline</time_frame>
    <description>Molecular neuroimaging data measuring neurochemical composition profile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET imaging data</measure>
    <time_frame>Baseline</time_frame>
    <description>PET imaging data measuring receptor availability of GABA(gamma-aminobutyric acid) and Glutamate.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Genetic High Risk for Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Genetic High Risk</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      5-10mL of adipose cells in tumescent solution

      5-10mL of venous blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Subjects at genetic high risk for schizophrenia

          -  Healthy control
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        [Subjects at genetic high risk for schizophrenia]

          -  Healthy without any Axis I mental disorder

          -  Is a monozygotic twin of a patient with schizophrenia OR Has at least two family
             members of schizophrenia in the pedigree, including at least one 1st-degree family
             member

        [Healthy Control]

          -  Healthy without any Axis I mental disorder

          -  No family members of schizophrenia in the pedigree to the 3rd degree

        Exclusion Criteria:

          -  Significant neurological or medical illness

          -  Psychotic symptoms

          -  Substance abuse

          -  Suicidal risk

          -  Blindness or hearing loss

          -  Taking aspirin, warfarin or hormonal agents

          -  Pregnancy or lactation

          -  Susceptibility for keloid formation

          -  Allergy to lidocaine

          -  History of significant head trauma or loss of consciousness

          -  Mental retardation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Soo Kwon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Soo Kwon, M.D, Ph.D</last_name>
    <phone>+82-2-2072-2450</phone>
    <email>kwonjs@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myongwuk Chon, M.D</last_name>
      <phone>+82-10-7641-5085</phone>
      <email>mwchon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jun Soo Kwon, M.D, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>September 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2013</study_first_posted>
  <last_update_submitted>December 4, 2013</last_update_submitted>
  <last_update_submitted_qc>December 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>stem cells</keyword>
  <keyword>neurons</keyword>
  <keyword>genetic hish risk for schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

